Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more
Shenzhen Chipscreen Biosciences Co (688321) - Net Assets
Latest net assets as of September 2025: CN¥1.66 Billion CNY
Based on the latest financial reports, Shenzhen Chipscreen Biosciences Co (688321) has net assets worth CN¥1.66 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.63 Billion) and total liabilities (CN¥1.98 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.66 Billion |
| % of Total Assets | 45.58% |
| Annual Growth Rate | 28.45% |
| 5-Year Change | 5.84% |
| 10-Year Change | N/A |
| Growth Volatility | 71.01 |
Shenzhen Chipscreen Biosciences Co - Net Assets Trend (2016–2024)
This chart illustrates how Shenzhen Chipscreen Biosciences Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shenzhen Chipscreen Biosciences Co (2016–2024)
The table below shows the annual net assets of Shenzhen Chipscreen Biosciences Co from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.58 Billion | -7.53% |
| 2023-12-31 | CN¥1.71 Billion | +8.52% |
| 2022-12-31 | CN¥1.58 Billion | +11.15% |
| 2021-12-31 | CN¥1.42 Billion | -5.10% |
| 2020-12-31 | CN¥1.49 Billion | +3.28% |
| 2019-12-31 | CN¥1.45 Billion | +203.28% |
| 2018-12-31 | CN¥476.90 Million | +5.85% |
| 2017-12-31 | CN¥450.55 Million | +111.13% |
| 2016-12-31 | CN¥213.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Chipscreen Biosciences Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10806100360.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.01 Million | 0.19% |
| Common Stock | CN¥407.80 Million | 25.79% |
| Other Comprehensive Income | CN¥131.84 Million | 8.34% |
| Other Components | CN¥1.04 Billion | 65.68% |
| Total Equity | CN¥1.58 Billion | 100.00% |
Shenzhen Chipscreen Biosciences Co Competitors by Market Cap
The table below lists competitors of Shenzhen Chipscreen Biosciences Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Suess Microtec SE
LSE:0Q3C
|
$1.13 Billion |
|
Ladder Capital Corp Class A
NYSE:LADR
|
$1.13 Billion |
|
The Bank of East Asia Limited
PINK:BKEAF
|
$1.13 Billion |
|
Visual Photonics Epitaxy Co Ltd
TW:2455
|
$1.13 Billion |
|
Leroy Seafood Group ASA
LSE:0GM2
|
$1.13 Billion |
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
$1.13 Billion |
|
Birchcliff Energy Ltd.
PINK:BIREF
|
$1.13 Billion |
|
Paladin Energy Ltd
OTCQX:PALAF
|
$1.13 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Chipscreen Biosciences Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,586,125,125 to 1,581,098,748, a change of -5,026,377 (-0.3%).
- Net loss of 114,570,598 reduced equity.
- Dividend payments of 27,628,241 reduced retained earnings.
- Share repurchases of 15,000,000 reduced equity.
- Other comprehensive income increased equity by 78,373,504.
- Other factors increased equity by 73,798,958.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-114.57 Million | -7.25% |
| Dividends Paid | CN¥27.63 Million | -1.75% |
| Share Repurchases | CN¥15.00 Million | -0.95% |
| Other Comprehensive Income | CN¥78.37 Million | +4.96% |
| Other Changes | CN¥73.80 Million | +4.67% |
| Total Change | CN¥- | -0.32% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Chipscreen Biosciences Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 46.99x to 7.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.65 | CN¥30.40 | x |
| 2017-12-31 | CN¥1.29 | CN¥30.40 | x |
| 2018-12-31 | CN¥1.33 | CN¥30.40 | x |
| 2019-12-31 | CN¥3.53 | CN¥30.40 | x |
| 2020-12-31 | CN¥3.64 | CN¥30.40 | x |
| 2021-12-31 | CN¥3.46 | CN¥30.40 | x |
| 2022-12-31 | CN¥3.72 | CN¥30.40 | x |
| 2023-12-31 | CN¥3.89 | CN¥30.40 | x |
| 2024-12-31 | CN¥3.88 | CN¥30.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Chipscreen Biosciences Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.41%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 2.06x
- Recent ROE (-7.25%) is below the historical average (2.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 2.46% | 6.14% | 0.21x | 1.89x | CN¥-16.10 Million |
| 2017 | 5.34% | 21.79% | 0.17x | 1.46x | CN¥-20.98 Million |
| 2018 | 6.53% | 21.10% | 0.21x | 1.50x | CN¥-16.52 Million |
| 2019 | 1.34% | 11.17% | 0.10x | 1.17x | CN¥-125.21 Million |
| 2020 | 2.08% | 11.52% | 0.16x | 1.16x | CN¥-118.34 Million |
| 2021 | 1.55% | 5.10% | 0.23x | 1.34x | CN¥-119.80 Million |
| 2022 | 1.15% | 3.30% | 0.18x | 1.91x | CN¥-134.06 Million |
| 2023 | 5.60% | 16.96% | 0.16x | 2.02x | CN¥-69.77 Million |
| 2024 | -7.25% | -17.41% | 0.20x | 2.06x | CN¥-272.68 Million |
Industry Comparison
This section compares Shenzhen Chipscreen Biosciences Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Chipscreen Biosciences Co (688321) | CN¥1.66 Billion | 2.46% | 1.19x | $1.13 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |